NASDAQ:KTOV - KITOV PHARMA LT/S Stock Price, News, & Analysis Sign in or create an account to add this stock to your watchlist. Get Started $0.9150 -0.13 (-12.44 %) (As of 12/17/2018 06:47 AM ET)Previous Close$1.0401Today's Range$0.8418 - $1.0752-Week Range$0.84 - $3.81Volume138,954 shsAverage Volume48,130 shsMarket Capitalization$14.42 millionP/E Ratio-0.70Dividend YieldN/ABeta2.65 ProfileDiscussionAnalyst RatingsChartFinancialsInstitutional OwnershipHeadlinesSEC FilingsSocial Media Share on FacebookShare on TwitterShare on LinkedInShare on RedditShare on StocktwitsPrint this articleShare by Email Kitov Pharma Ltd, through its subsidiaries, operates as a development stage biopharmaceutical company in Israel. It develops combination drugs for the simultaneous treatment of pain caused by osteoarthritis and hypertension. The company's lead drug candidate is KIT-302, a fixed dosage combination product based on the generic drugs celecoxib and amlodipine besylate that has completed its Phase III clinical study. It is also developing NT219, a small molecule that targets two pathways involved in cancer drug resistance. The company was formerly known as Kitov Pharmaceuticals Holdings Ltd. and changed its name to Kitov Pharma Ltd in January 2018. Kitov Pharma Ltd was founded in 2010 and is headquartered in Tel Aviv, Israel. Receive KTOV News and Ratings via Email Sign-up to receive the latest news and ratings for KTOV and its competitors with MarketBeat's FREE daily newsletter. Industry, Sector and Symbol Stock Exchange NASDAQ Industry Pharmaceutical preparations Sub-IndustryN/A SectorMedical Current SymbolNASDAQ:KTOV Previous Symbol CUSIPN/A Webwww.kitovpharma.com Phone972-3933-3121 Debt Debt-to-Equity RatioN/A Current Ratio1.68 Quick RatioN/A Price-To-Earnings Trailing P/E Ratio-0.70 Forward P/E Ratio-30.50 P/E GrowthN/A Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$0.77 per share Price / Book1.19 Profitability EPS (Most Recent Fiscal Year)N/A Net IncomeN/A Net MarginsN/A Return on EquityN/A Return on AssetsN/A Miscellaneous Employees1 Outstanding Shares15,760,000Market Cap$14.42 million OptionableNot Optionable KITOV PHARMA LT/S (NASDAQ:KTOV) Frequently Asked Questions What is KITOV PHARMA LT/S's stock symbol? KITOV PHARMA LT/S trades on the NASDAQ under the ticker symbol "KTOV." What price target have analysts set for KTOV? 1 Wall Street analysts have issued 1 year target prices for KITOV PHARMA LT/S's shares. Their predictions range from $12.50 to $12.50. On average, they expect KITOV PHARMA LT/S's share price to reach $12.50 in the next year. This suggests a possible upside of 1,266.1% from the stock's current price. View Analyst Price Targets for KITOV PHARMA LT/S. What is the consensus analysts' recommendation for KITOV PHARMA LT/S? 1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for KITOV PHARMA LT/S in the last year. There are currently 1 buy rating for the stock, resulting in a consensus recommendation of "Buy." View Analyst Ratings for KITOV PHARMA LT/S. What are Wall Street analysts saying about KITOV PHARMA LT/S stock? Here are some recent quotes from research analysts about KITOV PHARMA LT/S stock: 1. According to Zacks Investment Research, "Kitov Pharmaceuticals Holdings Ltd. is a pharmaceutical company which focused on the development of therapeutic candidates. The company's product candidate consists of KIT-302, is formulated for treatment of pain caused by osteoarthritis and hypertension, which can be pre-existing or caused by the treatment for OA. Kitov Pharmaceuticals Holdings Ltd. is based in Jerusalem, Israel. " (6/15/2018) 2. HC Wainwright analysts commented, "We remind investors that KIT-302, a combination drug intended to simultaneously treat osteoarthritis-related pain and hypertension (a common side effect of stand-alone drugs that treat osteoarthritis-related pain), is comprised of two FDA-approved drugs, celecoxib (Celebrex®), a non-steroidal anti-inflammatory COX-2 inhibitor (NSAID) for the treatment of pain caused by osteoarthritis, and amlodipine besylate (Norvasc®), a calcium channel blocker for lowering blood pressure. The approval decision date for KIT-302 is May 31, 2018. We consider the China licensing transaction to be evidence that Kitov is continuing to pursue initiatives to optimize the commercial value of its lead candidate, and remain confident that Consensi should be approved by the end of this month. We reiterate our Buy rating and 12-month price target of $10.00 per share." (5/14/2018) Has KITOV PHARMA LT/S been receiving favorable news coverage? Headlines about KTOV stock have been trending somewhat positive recently, according to InfoTrie. The research group identifies negative and positive media coverage by monitoring more than six thousand blog and news sources in real-time. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. KITOV PHARMA LT/S earned a daily sentiment score of 1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 4.0 out of 10, indicating that recent media coverage is somewhat unlikely to have an impact on the company's share price in the near term. Who are some of KITOV PHARMA LT/S's key competitors? Some companies that are related to KITOV PHARMA LT/S include Ophthotech (OPHT), Avenue Therapeutics (ATXI), Merrimack Pharmaceuticals (MACK), Aquinox Pharmaceuticals (AQXP), Vaccinex (VCNX), IntelGenx Technologies (IGXT), Acasti Pharma (ACST), Vistagen Therapeutics (VTGN), Trevena (TRVN), AEterna Zentaris (AEZS), OncoSec Medical (ONCS), Conatus Pharmaceuticals (CNAT), Nemus Bioscience (NMUS), Aptevo Therapeutics (APVO) and DiaMedica Therapeutics (DMCAF). Who are KITOV PHARMA LT/S's key executives? KITOV PHARMA LT/S's management team includes the folowing people: Dr. John Paul Waymack, Founder, Chairman & Chief Medical Officer (Age 66)Mr. Isaac Israel, CEO & Director (Age 40)Dr. Hadas Reuveni, Founder & CTO of TyrNovo (Age 51)Dr. Gil Ben-Menachem MSc, MBA, Ph.D., VP of Bus. Devel. & Director (Age 51)Mr. Simcha Rock CPA, MBA, Strategic Advisor & Director (Age 68) When did KITOV PHARMA LT/S IPO? (KTOV) raised $13 million in an IPO on Friday, November 20th 2015. The company issued 3,200,000 shares at $4.13 per share. Rodman & Renshaw (a unit of H.C. Wainwright & Co.,) and Joseph Gunnar acted as the underwriters for the IPO. How do I buy shares of KITOV PHARMA LT/S? Shares of KTOV can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Scottrade, Fidelity and Charles Schwab. What is KITOV PHARMA LT/S's stock price today? One share of KTOV stock can currently be purchased for approximately $0.9150. How big of a company is KITOV PHARMA LT/S? KITOV PHARMA LT/S has a market capitalization of $14.42 million. The company earns $-12,270,000.00 in net income (profit) each year or ($1.30) on an earnings per share basis. KITOV PHARMA LT/S employs 1 workers across the globe. What is KITOV PHARMA LT/S's official website? The official website for KITOV PHARMA LT/S is http://www.kitovpharma.com. How can I contact KITOV PHARMA LT/S? KITOV PHARMA LT/S's mailing address is One Azrieli Center Round Tower 132 Menachem Begin Road, Tel Aviv L3, 6701101. The company can be reached via phone at 972-3933-3121. MarketBeat Community Rating for KITOV PHARMA LT/S (NASDAQ KTOV)Community Ranking: 3.0 out of 5 ( )Outperform Votes: 119 (Vote Outperform)Underperform Votes: 80 (Vote Underperform)Total Votes: 199MarketBeat's community ratings are surveys of what our community members think about KITOV PHARMA LT/S and other stocks. Vote "Outperform" if you believe KTOV will outperform the S&P 500 over the long term. Vote "Underperform" if you believe KTOV will underperform the S&P 500 over the long term. You may vote once every thirty days. This page was last updated on 12/17/2018 by MarketBeat.com StaffFeatured Article: When is a capital gain realized?